european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
  • Science News
  • Resources

Manufacturing

CHO K1 cell line 27 hours

CHO Cell Lines for Recombinant Protein Production

Drug development, Drug product, Manufacturing
leading european cdmo

Leading European CDMO for Drug Product Manufacturing

Drug development, Drug product, Manufacturing
antibodies development best practices

Antibodies Development Best Practices for CDMO Collaboration

Drug development, Manufacturing, Monoclonal antibody
Biologics CDMO

Biologics CDMO Solutions for the Future of Therapeutics

Biologics, Drug development, Manufacturing
Bioprocess operation modes. Bioreactors used in pharmaceutical biotechnology.

Bioprocess Operation Modes and Advanced Bioreactor Technology

Cell culture, Drug substance, Manufacturing
Ion-exchange chromatography

Ion Exchange Chromatography in Monoclonal Antibodies Purification

Analytics, Manufacturing
optimal CHO cell culture upstream process

Metabolite and nutrient analysis as crucial components for optimal CHO cell culture upstream process

Cell culture, Drug substance, Manufacturing
Mycoplasma Contamination Risks in Biomanufacturing

Mycoplasma contamination in biopharmaceutical manufacturing

Biologics, Cell culture, Contamination, Manufacturing
Glycosylation's Impact on Antibody Effector Functions

Impact of glycosylation on the effector functions of monoclonal antibodies: a case study of rituximab

Bioanalytics, Biologics, Drug substance, Manufacturing
Previous 1 2 3

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap.

    Powered by

    Veneo